Gomez-Aleza et al. showed in their clinical and pre-clinical work that denosumab (a human IgG2 monoclonal anti-RANKL antibody) treatment could convert a tumor hostile to immune-mediated therapies in an immune-susceptible environment [7]. Here, TNFSF11 is linked to neoplasm.